

Cyrus Cai

☎ 13918200907 ✉ cyr0731@126.com 📍 Shanghai

EDUCATION BACKGROUND

Ruprecht-Karls-Universität Heidelberg QS Top100	Sep 2019 - Mar 2023
Doctor of Medicine (Immunology and stem cell)	Germany
Tongji University 211 985 Double 1st-Class	Jul 2016 - Jul 2019
Master of Clinical Medicine (Surgery)	Shanghai
Hunan University of Chinese Medicine Double 1st-Class	Sep 2011 - Jun 2016
Bachelor of Clinical Medicine	Hunan

PROFESSIONAL EXPERIENCE

Dizal Pharmaceutical (AstraZeneca Spin-off)	Sep 2023 - Present
Sr. Medical Scientist at Department of Drug Clinical Development	Shanghai

Contributed to the delivery of FDA/NMPA NDA submission, including CTD draft and review (summary of clinical/safety efficacy, SAE and death narrative, drug label); work as medical representative to support annual DUSR, PBREER, IB update; regularly input competitor landscape review/CDP plan; contributed to study design and study protocol and other medical documentation delivery; work as medical monitor in clinical trials across phase I to 3.

Project 1): A Phase 3 Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic NSCLC (CTR20231559; NCT05668988)

- Daily work: completed the eligibility check, medical training for CRO and internal team; contributed to IRB/EC documents (IB, CSP, ICF, Canada pre-CTA and CTA packages) for Canada and EMA CTA approval; EDC data review and clean; medical review of safety cases (SAE, SUSAR) and safety signals; supported institutional ethics Q & A and CTIS queries (RFI of European regulatory authorities) and site communication (mainly for site management, protocol interpretation and data entry issues).
- On-demand tasks: supported IDMC meeting data review and hands-on case narrative of SAEs; engaged in visits to European and local KoLs and centers, and offered medical inputs in local and global investigators' meetings (presentation of key study design, data interpretation and safety management).

Project 2): A Phase I Study to Assess the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced NSCLC (CTR20231559; NCT05926180)

- Daily work: engaged in cross-function cooperation for study setup, including the review of the third-party CRO, the medical evaluation of research centers; contributed to medical documents (CSP, ICF, IB, MMP, SAP, PD list, etc.) and eCRF designation, etc.; completed the eligibility check, medical training and EDC data review; supported IRB/EC Q & A and site communication; participated in the visiting activities of KoLs and SIVs and supported the data review meeting of investigators.
- By study completion: engaged in the on-site quality control and final data review of the study and delivered CSR for US FDA NDA submission of sunvozertinib in the second line treatment setting for EGFR exon20ins NSCLC.

Project 3): A Phase I/2 Study of PD-L1 Antibody Plus AZD4205 in EGFR Wild Type NSCLC

Project 4): A Phase I/2 Study of Combination of EGFR TKIs in EGFR Mutant NSCLC (IND)

Dizal Pharmaceutical (AstraZeneca Spin-off)	Mar 2023 - Sep 2023
Medical Scientist at Department of Drug Clinical Development	Shanghai

- Please refer to above information.

Universitätsklinikum Heidelberg	Oct 2019 - Mar 2023
Graduate Researcher	Germany

- Worked as graduate researcher at the division of internal medicine (hematology, oncology and immunology); cooperated with Orthopedic Regenerative Medicine Research Center at Heidelberg University Hospital, being involved in basic and clinical translational research by exploring the mechanism of stem cell and targeted therapy of arthritis by small molecules and antibodies.

Shanghai Tenth People's Hospital Affiliated to Tongji University	Jul 2016 - Jul 2019
Surgical Resident	Shanghai

- Engaged in standardized training program of resident physicians, engaged in the first-line clinic work (patient admission, medical record writing, surgical setting, complication prevention and treatment, etc.). Obtained the qualification of China Practicing Physician and the National Surgical Residence Training Certificate.

SKILLS, CERTIFICATIONS & OTHERS

- **Languages:** English (IELTS 7.0), Mandarin (Native)
- **Skills:** Office, Data analysis, Literature review
- **Certifications:** Physician Practitioner (2017), National Resident Standardized Training (2019)

HONORS & AWARDS

China Scholarship Council Scholarship	2019
European Forum for Rheumatology Research (Young Scientist Fund)	2022

PUBLICATIONS

- B-cell inflammatory signals attenuate chondrogenesis of human mesenchymal stem cells via developmental signaling pathways. (first Author, 2022 European Rheumatology Research Forum, Young Scientist Award poster presentation)
- Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment (second author, 2023 ACR Congress poster presentation)
- Exploring the relationship between inflammation and ossification of ankylosing spondylitis based on ossification related signaling pathways. Chinese Journal of Rheumatology 2015.(first Author)
- Degradability, bioactivity, and osteogenesis of biocomposite scaffolds of lithium-containing mesoporous bioglass and mPEG-PLGA-b-PLL copolymer. Int J Nanomedicine 2015. (first author)